Oncology Market in India to 2017 - Limited Patient Affordability for High Priced Biologics Lowers Market Potential
Summary
GBI Research, the leading business intelligence provider, has released its latest research, “Oncology Market in India to 2017 - Limited Patient Affordability for High Priced Biologics Lowers Market Potential”, which provides insights into oncology sales and price forecasts until 2017. The report also examines the Indian oncology treatment usage patterns. In addition, the report also includes insights into the oncology R&D pipeline. The report provides an in-depth analysis of the top five oncology therapeutic indications, which are breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin’s Lymphoma (NHL).
Scope
The report covers:
Reasons to buy
The report will assist business development and marketing executives to strategize their product launches, by allowing them to:
Summary
GBI Research, the leading business intelligence provider, has released its latest research, “Oncology Market in India to 2017 - Limited Patient Affordability for High Priced Biologics Lowers Market Potential”, which provides insights into oncology sales and price forecasts until 2017. The report also examines the Indian oncology treatment usage patterns. In addition, the report also includes insights into the oncology R&D pipeline. The report provides an in-depth analysis of the top five oncology therapeutic indications, which are breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin’s Lymphoma (NHL).
Scope
The report covers:
- Data and analysis on the oncology market in India.
- Annualized market data for the oncology market from 2002 to 2009, with forecasts to 2017.
- Market data on the therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population and treated population.
- Key drivers and restraints that have had a significant impact on the market and on each indication.
- The competitive landscape of the oncology market includes both Indian players and foreign players.
- Key M&A activities and Licensing Agreements that took place from 2004 to 2010 in the Indian oncology market.
Reasons to buy
The report will assist business development and marketing executives to strategize their product launches, by allowing them to:
- Build effective strategies to launch their pipeline products by identifying potential of the market.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying each indication’s growth rate.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 ONCOLOGY MARKET IN INDIA: INTRODUCTION
2.1 GBI Research Report Guidance
3 ONCOLOGY MARKET IN INDIA: MARKET CHARACTERIZATION
3.1 Market Size
3.2 Annual Cost of Treatment
3.3 Treatment Usage Pattern
3.3.1 Diseased Population
3.3.2 Treated Population
3.4 Drivers
3.4.1 High Spending By Big Pharmaceutical Companies for Drug Trials
3.4.2 Larger Population Base
3.4.3 High Government Support and Initiatives
3.5 Barriers
3.5.1 Counterfeit Medical Products
3.5.2 Unfavorable Patent Law for Bigger Companies
3.5.3 Restrictive Pricing and Reimbursement Policies Causing Serious Problems in the Cancer Market Growth
3.5.4 Poor Infrastructure and Insufficient Trained Manpower
3.5.5 More than 80 Molecules to be launched Over the Next Seven Years, Leading to More Competition
3.6 Case Studies
3.6.1 Unfavorable Patent Law for Bigger Foreign Companies, Roche versus Cipla
3.6.2 Unfavorable Patent Law for Bigger Foreign Companies, Novartis – Glivec
4 ONCOLOGY MARKET IN INDIA: THERAPEUTIC LANDSCAPE
4.1 Introduction
4.2 Breast Cancer
4.2.1 Market Size
4.2.2 Average Annual Cost of Treatment
4.2.3 Treatment Usage Pattern
4.2.4 Drivers
4.2.5 Restraints
4.3 Colorectal Cancer
4.3.1 Market Size
4.3.2 Annual Cost of Treatment
4.3.3 Treatment Usage Pattern
4.3.4 Drivers
4.3.5 Restraints
4.4 Prostate Cancer
4.4.1 Market Size
4.4.2 Annual Cost of Treatment
4.4.3 Drivers
4.4.4 Restraints
4.4.5 Treatment Usage Pattern
4.5 Lung Cancer
4.5.1 Market Size
4.5.2 Annual Cost of Treatment
4.5.3 Drivers
4.5.4 Restraints
4.5.5 Treatment Usage Pattern
4.6 Non-Hodgkin’s Lymphoma
4.6.1 Market Size
4.6.2 Annual Cost of Treatment
4.6.3 Drivers
4.6.4 Restraints
4.6.5 Treatment Usage Pattern
5 ONCOLOGY IN INDIA: REGULATORY LANDSCAPE
5.1 Major Regulatory Bodies in India
5.1.1 The Central Drugs Standard Control Organization (CDSCO)
5.1.2 State Drug Regulatory Authority (SDRA)
5.2 IPR Protection in India
5.2.1 Effect of Patent Laws on Pharmaceutical Production in India
5.2.2 Key Impact of Newer Patent Laws on India
5.3 Key Regulations for Conducting Oncology Research in India
5.4 Government Initiatives to Support Oncology Research in India
5.4.1 Focus Areas
5.5 Oncology in India: Pricing and Reimbursements
5.5.1 Pricing of Oncology Drugs in India
5.5.2 Reimbursement of Oncology Drugs in India
6 ONCOLOGY IN INDIA: PIPELINE ANALYSIS
6.1 Key Area Focus for R&D in India
6.2 Pipeline Segmentation by Clinical Phase of Development
6.3 Pipeline Segmentation by Indication
6.3.1 Lung Cancer
6.3.2 Breast Cancer
6.3.3 Colorectal Cancer
6.3.4 Non-Hodgkin’s Lymphoma
6.3.5 Prostate Cancer
6.4 Key Late Stage Pipeline Drugs
6.4.1 Lung Cancer
6.4.2 Breast Cancer
6.4.3 Colorectal Cancer
6.4.4 Non-Hodgkin’s Lymphoma
6.4.5 Prostate Cancer
7 ONCOLOGY IN INDIA: COMPETITIVE LANDSCAPE
7.1 Key Indian Players in the Indian Oncology Market
7.1.1 Dr. Reddy’s Lab
7.1.2 Piramal Healthcare
7.1.3 Biocon Limited
7.1.4 Cipla Ltd.
7.2 Key Foreign Players in the Indian Oncology Market
7.2.1 Sanofi-Aventis
7.2.2 F. Hoffmann-La Roche Ltd/Genentech, Inc.
7.2.3 AstraZeneca
7.2.4 GlaxoSmithKline
8 DEALS LANDSCAPE
8.1 Mergers and Acquisitions
8.1.1 Deals by Year
8.1.2 Deals by Type
8.1.3 Deal by Value
8.1.4 Top 10 M&A Deals
8.2 Licensing Agreements
8.2.1 Deals by Year
8.2.2 Deals by Value
8.2.3 Key Takeaway
8.2.4 Top 10 Licensing Deals
9 APPENDIX
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.3.4 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Sources
LIST OF TABLES
Table 1: Oncology Market, India, $m, 2002–2009
Table 2: Oncology Market, India, $m, 2009-2017
Table 3: Oncology Market, India, Annual Cost of Treatment, $, 2002–2009
Table 4: Oncology Market, India, Annual Cost of Treatment, $, 2009–2017
Table 5: Oncology Market, India, Treatment Usage Patterns, 2002–2009
Table 6: Oncology Market, India, Treatment Usage Patterns, 2009–2017
Table 7: Oncology Market, India, Breast Cancer, Market Size, ($m), 2002–2009
Table 8: Oncology Market, India, Breast Cancer, Market Size, ($m), 2009-2017
Table 9: Oncology Market, India, Breast Cancer, Average Annual Cost of Treatment, 2002-2009
Table 10: Oncology Market, India, Breast Cancer, Average Annual Cost of Treatment, 2009-2017
Table 11: Oncology Market, India, Breast Cancer, Treatment Usage Patterns, 2002–2009
Table 12: Oncology Market, India, Breast Cancer, Treatment Usage Patterns, 2009-2017
Table 13: Oncology Market, Colorectal Cancer, India, Market Size, ($m), 2002–2009
Table 14: Oncology Market, Colorectal Cancer, India, Market Size, ($m), 2009–2017
Table 15: Oncology Market, Colorectal Cancer, India, Annual Cost of Treatment, ($), 2002–2009
Table 16: Oncology Market, Colorectal Cancer, India, Annual Cost of Treatment, ($), 2009–2017
Table 17: Oncology Market, India, Colorectal Cancer, Treatment Usage Pattern, 2002-2009
Table 18: Oncology Market, India, Colorectal Cancer, Treatment Usage Pattern, 2009-2017
Table 19: Oncology Market, India, Prostate Cancer, Market Size, ($m), 2002–2009
Table 20: Oncology Market, India, Prostate Cancer, Market Size, ($m), 2009–2017
Table 21: Oncology Market, India, Prostate Cancer, Annual Cost of Treatment, ($), 2002–2009
Table 22: Oncology Market, India, Prostate Cancer, Annual Cost of Treatment, ($), 2009–2017
Table 23: Oncology Market, India, Prostate Cancer, Treatment Usage Pattern, 2002–2009
Table 24: Oncology Market, India, Prostate Cancer, Treatment Usage Pattern, 2009–2017
Table 25: Oncology Market, India, Lung Cancer, Market Size, ($m), 2002–2009
Table 26: Oncology Market, India, Lung Cancer, Market Size, ($m), 2009–2017
Table 27: Oncology Market, India, Lung Cancer, Average Annual Cost of Treatment, ($), 2002–2009
Table 28: Oncology Market, India, Lung Cancer, Average Annual Cost of Treatment, ($), 2009–2017
Table 29: Oncology Market, India, Lung Cancer, Treatment Usage Pattern, 2002–2009
Table 30: Oncology Market, India, Lung Cancer, Treatment Usage Pattern, 2009–2017
Table 31: Oncology Market, India, Non-Hodgkin’s Lymphoma, Market Size, ($m), 2002-2009
Table 32: Oncology Market, India, Non-Hodgkin’s Lymphoma, Market Size, ($m), 2009-2017
Table 33: Oncology Market, India, Non-Hodgkin’s Lymphoma, Average Annual Cost of Treatment, 2002-2009
Table 34: Oncology Market, India, Non-Hodgkin’s Lymphoma, Average Annual Cost of Treatment, 2009-2017
Table 35: Oncology Market, India, Non-Hodgkin’s Lymphoma, Treatment Usage Pattern, 2002-2009
Table 36: Oncology Market, India, Non-Hodgkin’s Lymphoma, Treatment Usage Pattern, 2009-2017
Table 37: Oncology Market, India, Competitive Landscape, Dr. Reddy’s, Marketed Products, 2009
Table 38: Oncology Market, India, Competitive Landscape, Dr. Reddy’s, Product Pipeline, 2009
Table 39: Oncology Market, India, Competitive Landscape, Dr. Reddy’s, M&A , Licensing Deals, 2009-2010
Table 40: Oncology Market, India, Competitive Landscape, Piramal Life Sciences, Product Pipeline, 2009
Table 41: Oncology Market, India, Competitive Landscape, Piramal Life Sciences, M&A Deals, 2009-2010
Table 42: Oncology Market, India, Competitive Landscape, Biocon Limited, Marketed Products, 2009
Table 43: Oncology Market, India, Competitive Landscape, Biocon Limited, Product Pipeline, 2009
Table 44: Oncology Market, India, Competitive Landscape, Cipla Ltd., M&A Deals, 2009-2010
Table 45: Oncology Market, India, Competitive Landscape, Key Foreign Players, Sanofi-Aventis, Major Marketed Products, 2009
Table 46: Oncology Market, India, Competitive Landscape, Key Foreign Players, Sanofi-Aventis, Major Pipeline Products, 2009
Table 47: Oncology Market, India, Competitive Landscape, Key Foreign Players, F. Hoffmann-La Roche Ltd., Major Marketed Products, 2009
Table 48: Oncology Market, India, Competitive Landscape, Key Foreign Players, F. Hoffmann-La Roche Ltd., Major Pipeline Products, 2009
Table 49: Oncology Market, India, Competitive Landscape, Key Foreign Players, AstraZeneca, Marketed Products, 2009
Table 50: Oncology Market, India, Competitive Landscape, Key Foreign Players, AstraZeneca, Oncology Pipeline, 2009
Table 51: Oncology Market, India, Competitive Landscape, Key Foreign Players, GlaxoSmithKline Pharmaceuticals Ltd, Marketed Products, 2009
Table 52: Oncology Market, India, Competitive Landscape, Key Foreign Players, GlaxoSmithKline Pharmaceuticals Ltd, Pipeline Products, 2009
Table 53: Oncology Market, India, Deals Landscape, M&A Deals, 2004-2010
LIST OF FIGURES
Figure 1: Oncology Market, India, $m, 2002-2017
Figure 2: Oncology Market, India, Annual Cost of Treatment, $, 2002-2017
Figure 3: Oncology Market, India, Treatment Usage Patterns, 2002-2017
Figure 4: Oncology Market, India, Total Diseased Population, 2002-2017
Figure 5: Oncology Market, India, Total Treated Population, 2002-2017
Figure 6: Oncology Market, India, Drivers and Restraints, 2009
Figure 7: Oncology Market, India, Case Studies, Roche versus Cipla, 2006-2010
Figure 8: Oncology Market, India, Case Studies, Novartis, 1993-2010
Figure 9: Oncology Market, India, Breast Cancer, Market Size, ($m), 2002-2017
Figure 10: Oncology Market, India, Breast Cancer, Average Annual Cost of Treatment, ($), 2002-2017
Figure 11: Oncology Market, India, Breast Cancer, Treatment Usage Pattern, 2002-2017
Figure 12: Oncology Market, India, Breast Cancer, Diseased Population, 2002-2017
Figure 13: Oncology Market, India, Breast Cancer, Treated Population, 2002-2017
Figure 14: Oncology Market, Colorectal Cancer, India, Market Size, ($m), 2002-2017
Figure 15: Oncology Market, Colorectal Cancer, India, Average Annual Cost of Treatment, ($), 2002-2017
Figure 16: Oncology Market, India, Colorectal Cancer, Treatment Usage Pattern, 2002-2017
Figure 17: Oncology Market, India, Colorectal Cancer, Diseased Population, 2002-2017
Figure 18: Oncology Market, India, Colorectal Cancer, Treated Population, 2002-2017
Figure 19: Oncology Market, India, Prostate Cancer, Market Size, ($m), 2002-2017
Figure 20: Oncology Market, India, Prostate Cancer, Average Annual Cost of Treatment, ($), 2002-2017
Figure 21: Oncology Market, India, Prostate Cancer, Treatment Usage Pattern, 2002-2017
Figure 22: Oncology Market, India, Prostate Cancer, Diseased Population, 2002-2017
Figure 23: Oncology Market, India, Prostate Cancer, Treated Population, 2002-2017
Figure 24: Oncology Market, India, Lung Cancer, Market Size, ($m), 2002-2017
Figure 25: Oncology Market, India, Lung Cancer, Average Annual Cost of Treatment, ($), 2002-2017
Figure 26: Oncology Market, India, Lung Cancer, Treatment Usage Pattern, 2002-2017
Figure 27: Oncology Market, India, Lung Cancer, Diseased Population, 2002-2017
Figure 28: Oncology Market, India, Lung Cancer, Treated Population, 2002-2017
Figure 29: Oncology Market, India, Non-Hodgkin’s Lymphoma, Market Size, ($m), 2002-2017
Figure 30: Oncology Market, India, Non-Hodgkin’s Lymphoma, Average Annual Cost of Treatment, ($), 2002-2017
Figure 31: Oncology Market, India, Non-Hodgkin’s Lymphoma, Treatment Usage Pattern, 2002-2017
Figure 32: Oncology Market, India, Non-Hodgkin’s Lymphoma, Diseased Population, 2002-2017
Figure 33: Oncology Market, India, Non-Hodgkin’s Lymphoma, Treated Population, 2002-2017
Figure 34: Oncology Market, India, Regulatory Landscape, Functions of CDSCO India, 2009
Figure 35: Oncology Market, India, Regulatory Landscape, Functions of SDRA India, 2009
Figure 36: Oncology Market, India, Regulatory Landscape, IPR Protection in India, 1963-2009
Figure 37: Oncology Market, India, Regulatory Landscape, Drug Approval Process Flow, 2009
Figure 38: Oncology Market, India, Regulatory Landscape, Number of Approved Clinical Trials by CDSCO, 2007-2010
Figure 39: Oncology Market, India, Regulatory Landscape, Current Pricing Practice in India, 2009
Figure 40: Oncology Market, Global Pipeline by Phase of Development, %, 2010
Figure 41: Oncology Market, Global Pipeline by Indication, %, 2010
Figure 42: Oncology Market, Lung Cancer, Global Pipeline by Phase of Development, %, 2010
Figure 43: Oncology Market, Breast Cancer, Global Pipeline by Phase of Development, %, 2010
Figure 44: Oncology Market, Colorectal Cancer, Global Pipeline by Phase of Development, %, 2010
Figure 45: Oncology Market, Non-Hodgkin’s Lymphoma, Global Pipeline by Phase of Development, %, 2010
Figure 46: Oncology Market, Prostate Cancer, Global Pipeline by Phase of Development, %, 2010
Figure 47: Oncology Market, India, Competitive Landscape, Dr. Reddy’s, SWOT Profile, 2009
Figure 48: Oncology Market, India, Competitive Landscape, Piramal Life Sciences, SWOT Profile, 2009
Figure 49: Oncology Market, India, Competitive Landscape, Biocon Limited, SWOT Profile, 2009
Figure 50: Oncology Market, India, Competitive Landscape, Cipla Ltd., SWOT Profile, 2009
Figure 51: Oncology Market, India, Competitive Landscape, Key Foreign Players, Sanofi-Aventis, SWOT Profile, 2009
Figure 52: Oncology Market, India, Competitive Landscape, Key Foreign Players, F. Hoffmann-La Roche Ltd., SWOT Profile, 2009
Figure 53: Oncology Market, India, Competitive Landscape, Key Foreign Players, AstraZeneca, SWOT Profile, 2009
Figure 54: Oncology Market, India, Competitive Landscape, Key Foreign Players, GlaxoSmithKline Pharmaceuticals Ltd, SWOT Profile, 2009
Figure 55: Oncology Market, India, Deals Landscape, M&A Deals, Deals By Year, 2009
Figure 56: Oncology Market, India, Deals Landscape, M&A Deals, Deals by Type, 2004-2010
Figure 57: Oncology Market, India, Deals Landscape, M&A Deals, Deals By Value, 2004-2010
Figure 58: Oncology Market, India, Deals Landscape, Licensing Deals, Deals By Year, 2006-2010
Figure 59: Oncology Market, India, Deals Landscape, Licensing Deals, Deals By Value, 2004-2010
COMPANIES MENTIONED
Dr. Reddy’s Lab
Piramal Healthcare
Biocon Limited
Cipla Ltd.
Sanofi-Aventis
F. Hoffmann-La Roche Ltd/Genentech, Inc.
AstraZeneca
GlaxoSmithKline
1.1 List of Tables
1.2 List of Figures
2 ONCOLOGY MARKET IN INDIA: INTRODUCTION
2.1 GBI Research Report Guidance
3 ONCOLOGY MARKET IN INDIA: MARKET CHARACTERIZATION
3.1 Market Size
3.2 Annual Cost of Treatment
3.3 Treatment Usage Pattern
3.3.1 Diseased Population
3.3.2 Treated Population
3.4 Drivers
3.4.1 High Spending By Big Pharmaceutical Companies for Drug Trials
3.4.2 Larger Population Base
3.4.3 High Government Support and Initiatives
3.5 Barriers
3.5.1 Counterfeit Medical Products
3.5.2 Unfavorable Patent Law for Bigger Companies
3.5.3 Restrictive Pricing and Reimbursement Policies Causing Serious Problems in the Cancer Market Growth
3.5.4 Poor Infrastructure and Insufficient Trained Manpower
3.5.5 More than 80 Molecules to be launched Over the Next Seven Years, Leading to More Competition
3.6 Case Studies
3.6.1 Unfavorable Patent Law for Bigger Foreign Companies, Roche versus Cipla
3.6.2 Unfavorable Patent Law for Bigger Foreign Companies, Novartis – Glivec
4 ONCOLOGY MARKET IN INDIA: THERAPEUTIC LANDSCAPE
4.1 Introduction
4.2 Breast Cancer
4.2.1 Market Size
4.2.2 Average Annual Cost of Treatment
4.2.3 Treatment Usage Pattern
4.2.4 Drivers
4.2.5 Restraints
4.3 Colorectal Cancer
4.3.1 Market Size
4.3.2 Annual Cost of Treatment
4.3.3 Treatment Usage Pattern
4.3.4 Drivers
4.3.5 Restraints
4.4 Prostate Cancer
4.4.1 Market Size
4.4.2 Annual Cost of Treatment
4.4.3 Drivers
4.4.4 Restraints
4.4.5 Treatment Usage Pattern
4.5 Lung Cancer
4.5.1 Market Size
4.5.2 Annual Cost of Treatment
4.5.3 Drivers
4.5.4 Restraints
4.5.5 Treatment Usage Pattern
4.6 Non-Hodgkin’s Lymphoma
4.6.1 Market Size
4.6.2 Annual Cost of Treatment
4.6.3 Drivers
4.6.4 Restraints
4.6.5 Treatment Usage Pattern
5 ONCOLOGY IN INDIA: REGULATORY LANDSCAPE
5.1 Major Regulatory Bodies in India
5.1.1 The Central Drugs Standard Control Organization (CDSCO)
5.1.2 State Drug Regulatory Authority (SDRA)
5.2 IPR Protection in India
5.2.1 Effect of Patent Laws on Pharmaceutical Production in India
5.2.2 Key Impact of Newer Patent Laws on India
5.3 Key Regulations for Conducting Oncology Research in India
5.4 Government Initiatives to Support Oncology Research in India
5.4.1 Focus Areas
5.5 Oncology in India: Pricing and Reimbursements
5.5.1 Pricing of Oncology Drugs in India
5.5.2 Reimbursement of Oncology Drugs in India
6 ONCOLOGY IN INDIA: PIPELINE ANALYSIS
6.1 Key Area Focus for R&D in India
6.2 Pipeline Segmentation by Clinical Phase of Development
6.3 Pipeline Segmentation by Indication
6.3.1 Lung Cancer
6.3.2 Breast Cancer
6.3.3 Colorectal Cancer
6.3.4 Non-Hodgkin’s Lymphoma
6.3.5 Prostate Cancer
6.4 Key Late Stage Pipeline Drugs
6.4.1 Lung Cancer
6.4.2 Breast Cancer
6.4.3 Colorectal Cancer
6.4.4 Non-Hodgkin’s Lymphoma
6.4.5 Prostate Cancer
7 ONCOLOGY IN INDIA: COMPETITIVE LANDSCAPE
7.1 Key Indian Players in the Indian Oncology Market
7.1.1 Dr. Reddy’s Lab
7.1.2 Piramal Healthcare
7.1.3 Biocon Limited
7.1.4 Cipla Ltd.
7.2 Key Foreign Players in the Indian Oncology Market
7.2.1 Sanofi-Aventis
7.2.2 F. Hoffmann-La Roche Ltd/Genentech, Inc.
7.2.3 AstraZeneca
7.2.4 GlaxoSmithKline
8 DEALS LANDSCAPE
8.1 Mergers and Acquisitions
8.1.1 Deals by Year
8.1.2 Deals by Type
8.1.3 Deal by Value
8.1.4 Top 10 M&A Deals
8.2 Licensing Agreements
8.2.1 Deals by Year
8.2.2 Deals by Value
8.2.3 Key Takeaway
8.2.4 Top 10 Licensing Deals
9 APPENDIX
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.3.4 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Sources
LIST OF TABLES
Table 1: Oncology Market, India, $m, 2002–2009
Table 2: Oncology Market, India, $m, 2009-2017
Table 3: Oncology Market, India, Annual Cost of Treatment, $, 2002–2009
Table 4: Oncology Market, India, Annual Cost of Treatment, $, 2009–2017
Table 5: Oncology Market, India, Treatment Usage Patterns, 2002–2009
Table 6: Oncology Market, India, Treatment Usage Patterns, 2009–2017
Table 7: Oncology Market, India, Breast Cancer, Market Size, ($m), 2002–2009
Table 8: Oncology Market, India, Breast Cancer, Market Size, ($m), 2009-2017
Table 9: Oncology Market, India, Breast Cancer, Average Annual Cost of Treatment, 2002-2009
Table 10: Oncology Market, India, Breast Cancer, Average Annual Cost of Treatment, 2009-2017
Table 11: Oncology Market, India, Breast Cancer, Treatment Usage Patterns, 2002–2009
Table 12: Oncology Market, India, Breast Cancer, Treatment Usage Patterns, 2009-2017
Table 13: Oncology Market, Colorectal Cancer, India, Market Size, ($m), 2002–2009
Table 14: Oncology Market, Colorectal Cancer, India, Market Size, ($m), 2009–2017
Table 15: Oncology Market, Colorectal Cancer, India, Annual Cost of Treatment, ($), 2002–2009
Table 16: Oncology Market, Colorectal Cancer, India, Annual Cost of Treatment, ($), 2009–2017
Table 17: Oncology Market, India, Colorectal Cancer, Treatment Usage Pattern, 2002-2009
Table 18: Oncology Market, India, Colorectal Cancer, Treatment Usage Pattern, 2009-2017
Table 19: Oncology Market, India, Prostate Cancer, Market Size, ($m), 2002–2009
Table 20: Oncology Market, India, Prostate Cancer, Market Size, ($m), 2009–2017
Table 21: Oncology Market, India, Prostate Cancer, Annual Cost of Treatment, ($), 2002–2009
Table 22: Oncology Market, India, Prostate Cancer, Annual Cost of Treatment, ($), 2009–2017
Table 23: Oncology Market, India, Prostate Cancer, Treatment Usage Pattern, 2002–2009
Table 24: Oncology Market, India, Prostate Cancer, Treatment Usage Pattern, 2009–2017
Table 25: Oncology Market, India, Lung Cancer, Market Size, ($m), 2002–2009
Table 26: Oncology Market, India, Lung Cancer, Market Size, ($m), 2009–2017
Table 27: Oncology Market, India, Lung Cancer, Average Annual Cost of Treatment, ($), 2002–2009
Table 28: Oncology Market, India, Lung Cancer, Average Annual Cost of Treatment, ($), 2009–2017
Table 29: Oncology Market, India, Lung Cancer, Treatment Usage Pattern, 2002–2009
Table 30: Oncology Market, India, Lung Cancer, Treatment Usage Pattern, 2009–2017
Table 31: Oncology Market, India, Non-Hodgkin’s Lymphoma, Market Size, ($m), 2002-2009
Table 32: Oncology Market, India, Non-Hodgkin’s Lymphoma, Market Size, ($m), 2009-2017
Table 33: Oncology Market, India, Non-Hodgkin’s Lymphoma, Average Annual Cost of Treatment, 2002-2009
Table 34: Oncology Market, India, Non-Hodgkin’s Lymphoma, Average Annual Cost of Treatment, 2009-2017
Table 35: Oncology Market, India, Non-Hodgkin’s Lymphoma, Treatment Usage Pattern, 2002-2009
Table 36: Oncology Market, India, Non-Hodgkin’s Lymphoma, Treatment Usage Pattern, 2009-2017
Table 37: Oncology Market, India, Competitive Landscape, Dr. Reddy’s, Marketed Products, 2009
Table 38: Oncology Market, India, Competitive Landscape, Dr. Reddy’s, Product Pipeline, 2009
Table 39: Oncology Market, India, Competitive Landscape, Dr. Reddy’s, M&A , Licensing Deals, 2009-2010
Table 40: Oncology Market, India, Competitive Landscape, Piramal Life Sciences, Product Pipeline, 2009
Table 41: Oncology Market, India, Competitive Landscape, Piramal Life Sciences, M&A Deals, 2009-2010
Table 42: Oncology Market, India, Competitive Landscape, Biocon Limited, Marketed Products, 2009
Table 43: Oncology Market, India, Competitive Landscape, Biocon Limited, Product Pipeline, 2009
Table 44: Oncology Market, India, Competitive Landscape, Cipla Ltd., M&A Deals, 2009-2010
Table 45: Oncology Market, India, Competitive Landscape, Key Foreign Players, Sanofi-Aventis, Major Marketed Products, 2009
Table 46: Oncology Market, India, Competitive Landscape, Key Foreign Players, Sanofi-Aventis, Major Pipeline Products, 2009
Table 47: Oncology Market, India, Competitive Landscape, Key Foreign Players, F. Hoffmann-La Roche Ltd., Major Marketed Products, 2009
Table 48: Oncology Market, India, Competitive Landscape, Key Foreign Players, F. Hoffmann-La Roche Ltd., Major Pipeline Products, 2009
Table 49: Oncology Market, India, Competitive Landscape, Key Foreign Players, AstraZeneca, Marketed Products, 2009
Table 50: Oncology Market, India, Competitive Landscape, Key Foreign Players, AstraZeneca, Oncology Pipeline, 2009
Table 51: Oncology Market, India, Competitive Landscape, Key Foreign Players, GlaxoSmithKline Pharmaceuticals Ltd, Marketed Products, 2009
Table 52: Oncology Market, India, Competitive Landscape, Key Foreign Players, GlaxoSmithKline Pharmaceuticals Ltd, Pipeline Products, 2009
Table 53: Oncology Market, India, Deals Landscape, M&A Deals, 2004-2010
LIST OF FIGURES
Figure 1: Oncology Market, India, $m, 2002-2017
Figure 2: Oncology Market, India, Annual Cost of Treatment, $, 2002-2017
Figure 3: Oncology Market, India, Treatment Usage Patterns, 2002-2017
Figure 4: Oncology Market, India, Total Diseased Population, 2002-2017
Figure 5: Oncology Market, India, Total Treated Population, 2002-2017
Figure 6: Oncology Market, India, Drivers and Restraints, 2009
Figure 7: Oncology Market, India, Case Studies, Roche versus Cipla, 2006-2010
Figure 8: Oncology Market, India, Case Studies, Novartis, 1993-2010
Figure 9: Oncology Market, India, Breast Cancer, Market Size, ($m), 2002-2017
Figure 10: Oncology Market, India, Breast Cancer, Average Annual Cost of Treatment, ($), 2002-2017
Figure 11: Oncology Market, India, Breast Cancer, Treatment Usage Pattern, 2002-2017
Figure 12: Oncology Market, India, Breast Cancer, Diseased Population, 2002-2017
Figure 13: Oncology Market, India, Breast Cancer, Treated Population, 2002-2017
Figure 14: Oncology Market, Colorectal Cancer, India, Market Size, ($m), 2002-2017
Figure 15: Oncology Market, Colorectal Cancer, India, Average Annual Cost of Treatment, ($), 2002-2017
Figure 16: Oncology Market, India, Colorectal Cancer, Treatment Usage Pattern, 2002-2017
Figure 17: Oncology Market, India, Colorectal Cancer, Diseased Population, 2002-2017
Figure 18: Oncology Market, India, Colorectal Cancer, Treated Population, 2002-2017
Figure 19: Oncology Market, India, Prostate Cancer, Market Size, ($m), 2002-2017
Figure 20: Oncology Market, India, Prostate Cancer, Average Annual Cost of Treatment, ($), 2002-2017
Figure 21: Oncology Market, India, Prostate Cancer, Treatment Usage Pattern, 2002-2017
Figure 22: Oncology Market, India, Prostate Cancer, Diseased Population, 2002-2017
Figure 23: Oncology Market, India, Prostate Cancer, Treated Population, 2002-2017
Figure 24: Oncology Market, India, Lung Cancer, Market Size, ($m), 2002-2017
Figure 25: Oncology Market, India, Lung Cancer, Average Annual Cost of Treatment, ($), 2002-2017
Figure 26: Oncology Market, India, Lung Cancer, Treatment Usage Pattern, 2002-2017
Figure 27: Oncology Market, India, Lung Cancer, Diseased Population, 2002-2017
Figure 28: Oncology Market, India, Lung Cancer, Treated Population, 2002-2017
Figure 29: Oncology Market, India, Non-Hodgkin’s Lymphoma, Market Size, ($m), 2002-2017
Figure 30: Oncology Market, India, Non-Hodgkin’s Lymphoma, Average Annual Cost of Treatment, ($), 2002-2017
Figure 31: Oncology Market, India, Non-Hodgkin’s Lymphoma, Treatment Usage Pattern, 2002-2017
Figure 32: Oncology Market, India, Non-Hodgkin’s Lymphoma, Diseased Population, 2002-2017
Figure 33: Oncology Market, India, Non-Hodgkin’s Lymphoma, Treated Population, 2002-2017
Figure 34: Oncology Market, India, Regulatory Landscape, Functions of CDSCO India, 2009
Figure 35: Oncology Market, India, Regulatory Landscape, Functions of SDRA India, 2009
Figure 36: Oncology Market, India, Regulatory Landscape, IPR Protection in India, 1963-2009
Figure 37: Oncology Market, India, Regulatory Landscape, Drug Approval Process Flow, 2009
Figure 38: Oncology Market, India, Regulatory Landscape, Number of Approved Clinical Trials by CDSCO, 2007-2010
Figure 39: Oncology Market, India, Regulatory Landscape, Current Pricing Practice in India, 2009
Figure 40: Oncology Market, Global Pipeline by Phase of Development, %, 2010
Figure 41: Oncology Market, Global Pipeline by Indication, %, 2010
Figure 42: Oncology Market, Lung Cancer, Global Pipeline by Phase of Development, %, 2010
Figure 43: Oncology Market, Breast Cancer, Global Pipeline by Phase of Development, %, 2010
Figure 44: Oncology Market, Colorectal Cancer, Global Pipeline by Phase of Development, %, 2010
Figure 45: Oncology Market, Non-Hodgkin’s Lymphoma, Global Pipeline by Phase of Development, %, 2010
Figure 46: Oncology Market, Prostate Cancer, Global Pipeline by Phase of Development, %, 2010
Figure 47: Oncology Market, India, Competitive Landscape, Dr. Reddy’s, SWOT Profile, 2009
Figure 48: Oncology Market, India, Competitive Landscape, Piramal Life Sciences, SWOT Profile, 2009
Figure 49: Oncology Market, India, Competitive Landscape, Biocon Limited, SWOT Profile, 2009
Figure 50: Oncology Market, India, Competitive Landscape, Cipla Ltd., SWOT Profile, 2009
Figure 51: Oncology Market, India, Competitive Landscape, Key Foreign Players, Sanofi-Aventis, SWOT Profile, 2009
Figure 52: Oncology Market, India, Competitive Landscape, Key Foreign Players, F. Hoffmann-La Roche Ltd., SWOT Profile, 2009
Figure 53: Oncology Market, India, Competitive Landscape, Key Foreign Players, AstraZeneca, SWOT Profile, 2009
Figure 54: Oncology Market, India, Competitive Landscape, Key Foreign Players, GlaxoSmithKline Pharmaceuticals Ltd, SWOT Profile, 2009
Figure 55: Oncology Market, India, Deals Landscape, M&A Deals, Deals By Year, 2009
Figure 56: Oncology Market, India, Deals Landscape, M&A Deals, Deals by Type, 2004-2010
Figure 57: Oncology Market, India, Deals Landscape, M&A Deals, Deals By Value, 2004-2010
Figure 58: Oncology Market, India, Deals Landscape, Licensing Deals, Deals By Year, 2006-2010
Figure 59: Oncology Market, India, Deals Landscape, Licensing Deals, Deals By Value, 2004-2010
COMPANIES MENTIONED
Dr. Reddy’s Lab
Piramal Healthcare
Biocon Limited
Cipla Ltd.
Sanofi-Aventis
F. Hoffmann-La Roche Ltd/Genentech, Inc.
AstraZeneca
GlaxoSmithKline